77 related articles for article (PubMed ID: 23622590)
1. Monitoring of CD3(+) T-cell count in patients receiving antithymocyte globulin induction after cadaveric renal transplantation.
Ata P; Kara M; Özdemir E; Canbakan M; Gökçe AM; Bayraktar FA; Şahin G; Özel L; Titiz MI
Transplant Proc; 2013 Apr; 45(3):929-31. PubMed ID: 23622590
[TBL] [Abstract][Full Text] [Related]
2. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring.
Abouna GM; al-Abdullah IH; Kelly-Sullivan D; Kumar MS; Loose J; Phillips K; Yost S; Seirka D
Transplantation; 1995 Jun; 59(11):1564-8. PubMed ID: 7778170
[TBL] [Abstract][Full Text] [Related]
3. [Low-dose antithymocyte globulins in kidney transplantation: results of a protocol of intermittent administration].
Mourad G; Portales P; Garrigue V; Djamali A; Bouloux C; Chong G; Clot J
Nephrologie; 2000; 21(5):253-8. PubMed ID: 11068775
[TBL] [Abstract][Full Text] [Related]
4. One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.
Colak T; Sevmiş S; Karakayali H; Moray G; Haberal M
Transplant Proc; 2008; 40(1):123-5. PubMed ID: 18261564
[TBL] [Abstract][Full Text] [Related]
5. [Importance of determining the absolute CD3+ lymphocyte count during induction therapy with antithymocyte globulin in kidney transplantation patients].
Drasković-Pavlović B; Hrvacević R; Ignjatović Lj; Popović P; Colić M
Vojnosanit Pregl; 2000; 57(3):285-90. PubMed ID: 11039308
[TBL] [Abstract][Full Text] [Related]
6. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
[TBL] [Abstract][Full Text] [Related]
7. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat).
Koch A; Daniel V; Dengler TJ; Schnabel PA; Hagl S; Sack FU
J Heart Lung Transplant; 2005 Jun; 24(6):708-13. PubMed ID: 15949731
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
9. Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring.
Djamali A; Turc-Baron C; Portales P; Leverson G; Chong G; Clot J; Mourad G
Transplantation; 2000 Mar; 69(5):799-805. PubMed ID: 10755529
[TBL] [Abstract][Full Text] [Related]
10. Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients.
Ternant D; Büchler M; Thibault G; Ohresser M; Watier H; Lebranchu Y; Paintaud G
Pharmacogenet Genomics; 2014 Jan; 24(1):26-34. PubMed ID: 24322002
[TBL] [Abstract][Full Text] [Related]
11. Long-term evolution of lymphocytes subsets after induction therapy based on continuous versus discontinuous administration of anti-thymocyte globulins in renal-transplant patients.
Esposito L; Kamar N; Tkaczuk J; Abbal M; Durand D; Rostaing L
Transplant Proc; 2005 Mar; 37(2):785-7. PubMed ID: 15848531
[TBL] [Abstract][Full Text] [Related]
12. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients.
Brennan DC; Schnitzler MA; Baty JD; Ceriotti CS; Lowell JA; Shenoy S; Howard TK; Woodward RS
Pharmacoeconomics; 1997 Mar; 11(3):237-45. PubMed ID: 10165313
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
Ravichandran P; Natrajan T; Jaganathan R
Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
[TBL] [Abstract][Full Text] [Related]
14. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
Bock HA; Gallati H; Zürcher RM; Bachofen M; Mihatsch MJ; Landmann J; Thiel G
Transplantation; 1995 Mar; 59(6):830-40. PubMed ID: 7701577
[TBL] [Abstract][Full Text] [Related]
15. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
Hariharan S; Alexander JW; Schroeder TJ; First MR
Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
[TBL] [Abstract][Full Text] [Related]
16. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
[TBL] [Abstract][Full Text] [Related]
17. Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients.
Wang D; Wu WZ; Yang SL; Chen JH; Tan JM
Chin Med J (Engl); 2006 Oct; 119(20):1683-8. PubMed ID: 17097014
[TBL] [Abstract][Full Text] [Related]
18. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.
Soulillou JP; Cantarovich D; Le Mauff B; Giral M; Robillard N; Hourmant M; Hirn M; Jacques Y
N Engl J Med; 1990 Apr; 322(17):1175-82. PubMed ID: 2157982
[TBL] [Abstract][Full Text] [Related]
20. One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.
Wang D; Chen JH; Wu WZ; Yang SL; Wu GJ; Wang H; Tan JM
Transplant Proc; 2007; 39(1):69-72. PubMed ID: 17275476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
